Arca
Skip to content
Tools
Tools

Carcinoma

Drug research and approvals for carcinoma: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 21, 2026, 4,641 studies of carcinoma are recruiting on ClinicalTrials.gov, Health Canada has authorized 238 drug trials for it since 2013, FDA has 54 approved and 182 open orphan designations naming it, and the EU has 68 authorised medicines for it.

  • Recruiting worldwide: 4,641
  • Trials authorized in Canada: 238
  • FDA orphan approvals: 54
  • EU medicines: 68

Recruiting now

Newest posted first, of 4,641 recruiting on ClinicalTrials.gov ↗

Drug pipeline

Each drug at the furthest stage it has reached for this condition or a subtype of it, from ChEMBL's drug indications

Approved 24 of 64

  • SorafenibHepatocellular cancer · Serine/threonine-protein kinase RAF inhibitor
  • PembrolizumabSquamous cell cancer · Programmed cell death protein 1 inhibitor
  • SunitinibRenal cell cancer · Macrophage colony stimulating factor receptor inhibitor
  • CetuximabSquamous cell cancer · Epidermal growth factor receptor erbB1 inhibitor
  • EverolimusRenal cell cancer · FK506-binding protein 1A inhibitor
  • BevacizumabRenal cell cancer · Vascular endothelial growth factor A inhibitor
  • NivolumabRenal cell cancer · Programmed cell death protein 1 inhibitor
  • PazopanibRenal cell cancer · Macrophage colony stimulating factor receptor inhibitor
  • AxitinibRenal cell cancer · Vascular endothelial growth factor receptor inhibitor
  • IpilimumabRenal cell cancer · Cytotoxic T-lymphocyte protein 4 inhibitor
  • LenvatinibRenal cell cancer · Vascular endothelial growth factor receptor inhibitor
  • TremelimumabHepatocellular cancer · Cytotoxic T-lymphocyte protein 4 inhibitor
  • CabozantinibRenal cell cancer · Vascular endothelial growth factor receptor 2 inhibitor
  • ToripalimabNasopharyngeal cancer · Programmed cell death protein 1 antagonist
  • TemsirolimusRenal cell cancer · FK506-binding protein 1A inhibitor
  • PaclitaxelTubulin inhibitor
  • BelzutifanRenal cell cancer · Endothelial PAS domain-containing protein 1 inhibitor
  • CarboplatinOvarian epithelial cancer · DNA inhibitor
  • AvelumabMerkel cell cancer · Programmed cell death 1 ligand 1 other
  • DocetaxelSquamous cell cancer of head and neck · Tubulin inhibitor
  • FluorouracilAdenocarcinoma · Thymidylate synthase inhibitor
  • TivozanibRenal cell cancer · Vascular endothelial growth factor receptor inhibitor
  • VandetanibMedullary cancer · Tyrosine-protein kinase SRC inhibitor
  • PemigatinibCholangiocarcinoma · Fibroblast growth factor receptor 2 inhibitor

Phase 3 12 of 159

  • CisplatinNasopharyngeal cancer · DNA inhibitor
  • OxaliplatinHepatocellular cancer · DNA inhibitor
  • LeucovorinHepatocellular cancer
  • GemcitabinePancreatic ductal cancer · Ribonucleoside-diphosphate reductase RR1 inhibitor
  • SintilimabHepatocellular cancer · Programmed cell death protein 1 antagonist
  • CamrelizumabHepatocellular cancer · Programmed cell death protein 1 antagonist
  • DurvalumabHepatocellular cancer · Programmed cell death 1 ligand 1 inhibitor
  • RivoceranibHepatocellular cancer · Vascular endothelial growth factor receptor 2 inhibitor
  • CapecitabineNasopharyngeal cancer · Thymidylate synthase inhibitor
  • RegorafenibHepatocellular cancer · Tyrosine-protein kinase ABL inhibitor
  • AldesleukinRenal cell cancer · Interleukin-2 receptor agonist
  • CadonilimabHepatocellular cancer · Programmed cell death protein 1 inhibitor

Phase 2 12 of 374

Phase 1 or earlier 12 of 223

How its trials ended

8,789 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 1,972 whose ending is known, 27% met their primary endpoint, 9% missed it and 64% stopped early.

  • Ongoing3,11635%
  • Completed, result not reported2,28426%
  • Status unknown1,41716%
  • Stopped: other or unclear6187%
  • Met its primary endpoint5286%
  • Stopped: enrollment or feasibility3063%
  • Missed its primary endpoint1852%
  • Stopped: sponsor or business decision1742%
  • Stopped: lack of efficacy901%
  • Stopped: funding531%
  • Stopped: safety18<1%

Trials authorized in Canada

The 10 newest of 238; search them all in Canada trials
Oct 22, 2026A phase 3, randomized, open-label, multicenter trial of amivantamab as sequential therapy following definitive, platinum-based, concurrent chemoradiotherapy,…Rybrevant (amivantamab0Johnson & JohnsonPending
Oct 2, 2026A phase 2/3 multicenter, randomized, open-label study of ASP-1929 photoimmunotherapy in combination with pembrolizumab versus standard of care in the…ASP-1929 (cetuximab-IR700)Rakuten MedicalPending
Aug 6, 2026Rosetta RCC-208: a phase 1/2 open-label, multi-center, randomized study of pumitamig alone or in combination with ipilimumab or cabozantinib in participants…Pumitamig (BMS-986545; BNT327) / Ipilimumab / CabozantinibBristol-Myers SquibbPending
Jun 29, 2026A phase 3, randomized, double-blind, study of belzutifan + zanzalintinib versus belzutifan + placebo in participants with advanced RCC who have progressed on…Belzutifan (MK-6482) / Zanzalintinib (XL092)Merck & Co. (MSD)Pending
Jun 26, 2026A phase 1/2, open-label trial to evaluate safety, immunogenicity, and anti-tumor activity of VB10.16 in combination with pembrolizumab in patients with…VB10.16 (abipapogene suvaplasmid) / PembrolizumabNykode Therapeutics AsaPending
Jun 10, 2026A phase 3, randomized, open-label study of belzutifan + zanzalintinib versus cabozantinib in participants with advanced RCC who experienced disease recurrence…Belzutifan (MK-6482) / Zanzalintinib (XL092)Merck & Co. (MSD)Ongoing
Apr 23, 2026A phase 1 first-in-human, open-label study evaluating the safety, pharmacokinetics, and efficacy of ABBV-711 as a monotherapy or in combination with…ABBV-711 / Budigalimab (ABBV-181)AbbVieOngoing
Mar 4, 2026A multicenter, open-label, phase 3 extension study to evaluate the longterm efficacy and safety in participants who are currently on treatment in a belzutifan…Belzutifan / LenvatinibMerck & Co. (MSD)Ongoing
Feb 26, 2026A randomized, open-label phase 3 study of azenosertib versus investigator’s choice of chemotherapy in platinum resistant high-grade serous ovarian, primary…AzenosertibK-Group Beta, Inc.Pending
Dec 19, 2025Capecitabine prior to tumor resection in entoncology (CAPTURE)CapecitabineResearch Institute of The McGill University Health CentrePending

FDA orphan designations

Approved first, then open designations, newest first; 15 of 236
May 15, 2025ZynyzIn combination with carboplatin and paclitaxel, for the first-line treatment of adult patients with inoperable locally recurrent or…Incyte CorporationApproved
Apr 23, 2025Penpulimab-kcqxIn combination with either cisplatin or carboplatin and gemcitabine, for the first-line treatment of adults with recurrent or metastatic…Akeso Biopharma Co., Ltd.Approved
Apr 11, 2025OpdivoIn combination with ipilimumab, for the first-line treatment of adult patients with unresectable or metastatic hepatocellular carcinoma…Bristol-Myers Squibb CompanyApproved
Mar 3, 2025TevimbraIn combination with platinum-containing chemotherapy, for the first-line treatment of adults with unresectable or metastatic esophageal…BeOne Medicines USA, Inc.Approved
Mar 13, 2024TevimbraAs a single agent, for the treatment of adult patients with unresectable or metastatic esophageal squamous cell carcinoma after prior…BeOne Medicines USA, Inc.Approved
Jan 25, 2024KeytrudaTreatment of patients with hepatocellular carcinoma (HCC) secondary to hepatitis B who have received prior systemic therapy other than a…MSD International Business GmbHApproved
Oct 31, 2023KeytrudaIn combination with gemcitabine and cisplatin, for the treatment of patients with locally advanced unresectable or metastatic biliary tract…MSD International Business GmbHApproved
Oct 27, 2023LoqtorziIn combination with cisplatin and gemcitabine, for the first-line treatment of adults with metastatic or with recurrent, locally advanced…Coherus BioSciences, Inc.Approved
Mar 22, 2023ZynyzTreatment of adult patients with metastatic or recurrent locally advanced Merkel cell carcinoma (MCC)Incyte CorporationApproved
Oct 21, 2022ImfinziIn combination with tremelimumab-actl for the treatment of adult patients with unresectable hepatocellular carcinoma (uHCC)AstraZeneca Pharmaceuticals LPApproved
Oct 21, 2022ImjudoIn combination with durvalumab for the treatment of adult patients with unresectable hepatocellular carcinoma (uHCC)AstraZeneca Pharmaceuticals LPApproved
May 27, 2022OpdivoIn combination with ipilimumab, for the first-line treatment of adult patients with unresectable advanced or metastatic esophageal squamous…Bristol-Myers Squibb CompanyApproved
May 27, 2022OpdivoIn combination with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adult patients with…Bristol-Myers Squibb CompanyApproved
Sep 17, 2021CabometyxTreatment of adult and pediatric patients 12 years of age and older with locally advanced or metastatic differentiated thyroid cancer (DTC)…Exelixis, Inc.Approved
Aug 13, 2021WeliregTreatment of adult patients with von Hippel-Lindau (VHL) disease who require therapy for associated renal cell carcinoma (RCC), central…Merck Sharp & Dohme, LLCApproved

Medicines authorised in the EU

Newest first; 15 of 68
May 29, 2026ImdylltraTarlatamab · orphanAmgen Europe B.V.EMA ↗
May 29, 2026ZepzelcaLurbinectedin · orphanPharma Mar S.A.EMA ↗
May 28, 2026AdstiladrinNadofaragene firadenovecFerring Pharmaceuticals A/SEMA ↗
Feb 16, 2026AnktivaNogapendekin alfa inbakiceptImmunitybio Ireland LimitedEMA ↗
Feb 12, 2025WeliregBelzutifanMerck Sharp & Dohme B.V.EMA ↗
Feb 3, 2025HetroniflySerplulimabAccord Healthcare S.L.U.EMA ↗
Jan 20, 2025LazcluzeLazertinibJanssen Cilag International NVEMA ↗
Jan 13, 2025AugtyroRepotrectinibBristol-Myers Squibb Pharma EEIGEMA ↗
Sep 19, 2024LoqtorziToripalimabTopalliance Biosciences Europe LimitedEMA ↗
Sep 19, 2024Axitinib AccordAxitinib · genericAccord Healthcare S.L.U.EMA ↗
Aug 22, 2024BalversaErdafitinibEMA ↗
Jul 26, 2024AvziviBevacizumab · biosimilarFGK Representative Service GmbHEMA ↗
Jul 24, 2024CejemlySugemalimabCstone Pharmaceuticals Ireland LimitedEMA ↗
Apr 19, 2024ZynyzRetifanlimab · orphanIncyte Biosciences Distribution B.V.EMA ↗
Jan 5, 2024KrazatiAdagrasibBristol-Myers Squibb Pharma EEIGEMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.